🟡 Preliminary Evidence
BioNTech and Pfizer presented encouraging early-stage data for their bispecific T-cell engager BNT327 in patients with advanced lung cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting 2026, according to STAT News coverage of the conference.
Key takeaways
- BioNTech and Pfizer presented data on BNT327 at ASCO 2026
- FDA’s Richard Pazdur discussed accelerated approval pathway reforms at the conference
- Multiple companies presented bispecific antibody data at the meeting
ASCO 2026 Conference Highlights
According to STAT News reporting from ASCO 2026, BioNTech and Pfizer presented data on their bispecific antibody BNT327 during the second day of the conference. The presentation was part of broader conference coverage that included promising developments in lung cancer treatment and new immunotherapy approaches.
FDA Accelerated Approval Reforms Discussed
As reported by STAT News, FDA official Richard Pazdur discussed reforms to accelerated approval pathways during ASCO 2026. The STAT News report characterized Pazdur’s comments as seeing “silver lining at FDA,” though specific details of the reforms were not detailed in the source material.
Multiple Companies Present Bispecific Data
STAT News coverage noted that the ASCO 2026 conference featured presentations from multiple pharmaceutical companies working on bispecific antibodies. According to the report, companies including Kelun and Merck also presented data during the conference, suggesting significant industry activity in this therapeutic area.
What this means
Frequently asked questions
What was presented at ASCO 2026?
According to STAT News, BioNTech and Pfizer presented data on their bispecific antibody BNT327, while other companies including Kelun and Merck also shared bispecific antibody research.
What did Richard Pazdur discuss?
STAT News reported that FDA’s Richard Pazdur discussed accelerated approval pathway reforms, with the publication characterizing his comments as seeing a “silver lining at FDA.”
When will these treatments be available?
The source material does not provide specific timelines for when any of the presented treatments might become available to patients.
The ASCO 2026 conference appears to have featured significant activity in bispecific antibody research, with multiple pharmaceutical companies presenting data on various approaches. The discussion of regulatory reforms by FDA officials suggests the regulatory landscape for cancer drug development may continue to evolve.
Source: STAT+: BioNTech and Pfizer tout bispecifics data at ASCO, and Pazdur sees silver lining at FDA
Was this article helpful?
Related Coverage
